Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Access Challenges for Septal Reduction Therapy Among Individuals With Obstructive Hypertrophic Cardiomyopathy.

Journal of the American Heart Association·2026
Same author

Real-world clinical and economic outcomes associated with supplemental oxygen therapy use among patients with fibrosing interstitial lung disease in the United States.

BMC pulmonary medicine·2025
Same author

Impact of In-Facility Nursing Assistant Training on CNA Retention in Long-Term Care.

Journal for nurses in professional development·2025
Same author

Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis-2 (AuToDeCRA-2) study: protocol for a single-centre, experimental medicine study investigating the route of delivery and potential efficacy of autologous tolerogenic dendritic cell (TolDC) therapy for rheumatoid arthritis.

Trials·2025
Same author

Impact of Intravenous Iron Replacement Therapy on Healthcare Costs for Patients with Iron Deficiency Anemia in the USA: A Retrospective Analysis.

Drugs - real world outcomes·2025
Same author

UTX (KDM6A) promotes differentiation noncatalytically in somatic self-renewing epithelia.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: Jun 15, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Pegloticase for chronic gout.

Amy Anderson1, Jasvinder A Singh

  • 1Medicine, Minneapolis VA Medical Center and University of Minnesota, One Veterans Drive, Minneapolis, MN, USA, 55417.

The Cochrane Database of Systematic Reviews
|March 19, 2010
PubMed
Summary
This summary is machine-generated.

Pegloticase shows varied efficacy in reducing uric acid levels in chronic gout patients. However, no placebo-controlled trials exist, highlighting the need for more research on its safety and benefits.

Related Experiment Videos

Last Updated: Jun 15, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Area of Science:

  • Rheumatology and Pharmacology
  • Clinical Trial Analysis

Background:

  • Chronic gout patients often have hyperuricemia and may be intolerant to existing urate-lowering therapies.
  • Pegloticase presents a potential novel therapeutic option for managing refractory chronic gout.

Purpose of the Study:

  • To evaluate the safety and efficacy of pegloticase in treating hyperuricemia in chronic gout.
  • Assess outcomes including adverse events, pain, function, flare frequency, quality of life, uric acid levels, and radiographic damage.

Main Methods:

  • Systematic literature search across six major databases (CENTRAL, MEDLINE, CINAHL, SPORTdiscus, EMBASE, Science Citation Index).
  • Inclusion criteria: Randomized controlled trials (RCTs) or controlled clinical trials comparing pegloticase doses against placebo or other interventions.
  • Data extraction by two independent reviewers; calculation of risk ratios and mean differences with 95% confidence intervals.

Main Results:

  • Only one open-label, phase-II RCT (n=41) met criteria, comparing four pegloticase doses without a placebo control.
  • Response rates (uric acid < 6 mg/dL for ≥80% of time) ranged from 52% to 88% across doses; no significant dose differences observed.
  • Common adverse events included nephrolithiasis, arthralgia, and anemia; 89% experienced gout flares. Secondary outcomes were not reported.

Conclusions:

  • No double-blind, placebo-controlled RCTs of pegloticase have been published to date.
  • Further evidence is required to comprehensively assess the risk-benefit profile of pegloticase for chronic gout management.